These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30623359)

  • 21. Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.
    Ciccocioppo R; Dos Santos CC; Baumgart DC; Cangemi GC; Cardinale V; Ciacci C; De Coppi P; Haldar D; Klersy C; Nostro MC; Ott M; Piemonti L; Tomei AA; Uygun B; Vetrano S; Orlando G
    Cytotherapy; 2018 Mar; 20(3):461-476. PubMed ID: 29398624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comprehensive assessment of ATMP. Difficulties and approaches].
    Thanner M; Nagel E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem Cell Technology for (Epi)genetic Brain Disorders.
    Riemens RJM; Soares ES; Esteller M; Delgado-Morales R
    Adv Exp Med Biol; 2017; 978():443-475. PubMed ID: 28523560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy in pediatrics - Clinical studies and approved drugs (as of 2023).
    Mohammadian Gol T; Zahedipour F; Trosien P; Ureña-Bailén G; Kim M; Antony JS; Mezger M
    Life Sci; 2024 Jul; 348():122685. PubMed ID: 38710276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on nonsense mediated decay reveal novel therapeutic options for genetic diseases.
    Bashyam MD
    Recent Pat DNA Gene Seq; 2009; 3(1):7-15. PubMed ID: 19149733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of Cellular and Tissue-based Products for Retinal Regenerative Medicine].
    Osakada F
    Yakugaku Zasshi; 2017; 137(1):23-29. PubMed ID: 28049891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status and perspective on regenerative medicine for spinal cord injury using iPS cell].
    Nakamura M; Toyama Y; Okano H
    Rinsho Shinkeigaku; 2013; 53(11):1013-5. PubMed ID: 24291863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
    Nagai S; Ozawa K
    Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Collaborative study on regulatory science for facilitating clinical development of gene therapy products for genetic diseases].
    Uchida E; Igarashi Y; Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):10-2. PubMed ID: 25707196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASGCT and JSGT Joint Position Statement on Human Genomic Editing.
    Friedmann T; Jonlin EC; King NMP; Torbett BE; Wivel NA; Kaneda Y; Sadelain M
    Mol Ther; 2015 Aug; 23(8):1282. PubMed ID: 26227250
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier.
    Papapetrou EP
    Adv Exp Med Biol; 2017; 1013():219-240. PubMed ID: 29127683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry.
    Maziarz RT; Arthurs J; Horwitz E
    Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European Society for Gene and Cell Therapy-Inaugural Learned Society in the Field Worldwide: A Vision on Its Birth, Life, and Prospects for Sustainability.
    Cohen-Haguenauer O
    Hum Gene Ther; 2017 Nov; 28(11):941-950. PubMed ID: 28859532
    [No Abstract]   [Full Text] [Related]  

  • 36. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Planning Split-Apheresis Designs for Demonstrating Comparability of Cellular and Gene Therapy Products.
    Burdick R; Hofer J; Karl A; Rushing H
    AAPS J; 2024 Sep; 26(6):105. PubMed ID: 39285085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An FDA perspective on preclinical development of cell-based regenerative medicine products.
    Bailey AM; Mendicino M; Au P
    Nat Biotechnol; 2014 Aug; 32(8):721-3. PubMed ID: 25093890
    [No Abstract]   [Full Text] [Related]  

  • 39. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010.
    Mason C; Manzotti E
    Regen Med; 2010 May; 5(3):307-13. PubMed ID: 20455641
    [No Abstract]   [Full Text] [Related]  

  • 40. Mesenchymal stem cell-based gene therapy: A promising therapeutic strategy.
    Mohammadian M; Abasi E; Akbarzadeh A
    Artif Cells Nanomed Biotechnol; 2016 Aug; 44(5):1206-11. PubMed ID: 26148175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.